arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

LIGAND PHARMACEUTICALS INC

LGND
$293.13 ▼ -7.75 (-2.58%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

LIGAND PHARMACEUTICALS INC shows strong fundamentals with top-quartile Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $5.7B
Dividend Yield
Revenue Growth 60.4%
Op. Margin 15.3%
ROIC 3.2%
FCF / Share $2.53
Trailing P/E 45.5x
Price / Book 5.7x
FCF Yield 0.9%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$268.09M
↑ +60.4%
Net Income Profit after all expenses
$124.45M
↑ +3186.6%
Operating Margin Operating profit as % of sales
15.3%
↑ +213.1% 67th
FCF / Share Free cash flow per share
$2.53
↓ -51.4%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
81
Returns
74
Financial Health
96
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 67 quarters